Mostrar el registro sencillo del ítem
dc.contributor.author
Perroud, Herman Andrés
dc.contributor.author
Rico, Maria Jose
dc.contributor.author
Alasino, Carlos
dc.contributor.author
Queralt, Fransisco
dc.contributor.author
Mainetti, Leandro Ernesto
dc.contributor.author
Pezzotto, Stella Maris
dc.contributor.author
Rozados, Viviana Rosa
dc.contributor.author
Scharovsky, Olga Graciela
dc.date.available
2017-08-03T18:01:10Z
dc.date.issued
2013-03
dc.identifier.citation
Perroud, Herman Andrés; Rico, Maria Jose; Alasino, Carlos; Queralt, Fransisco ; Mainetti, Leandro Ernesto; et al.; Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients; Future Medicine; Future Oncology; 9; 3; 3-2013; 451-462
dc.identifier.issn
1479-6694
dc.identifier.uri
http://hdl.handle.net/11336/21817
dc.description.abstract
Metronomic chemotherapy (MCT), the chronic administration, at regular intervals, of low doses of chemotherapeutic drugs without extended rest periods, allows chronic treatment with therapeutic efficacy and low toxicity. Our preclinical results suggested that combined MCT with cyclophosphamide and celecoxib could inhibit breast cancer growth. The aim of this study was to determine the toxicity, safety and efficacy of oral MCT with cyclophosphamide 50 mg per orem daily and celecoxib 400 mg (200 mg per orem two-times a day) in advanced breast cancer patients. During the first stage of the study, the therapeutic response consisted of prolonged stable disease for ≥24 weeks in six out of 15 (40%) patients with a median duration of 37.5 weeks and a partial response in one out of 15 (response rate: 6.7%) patients lasting 6 weeks . The overall clinical benefit rate was 46.7%. The median time to progression was 14 weeks. Progression-free survival at 24 weeks was 40% and the 1-year overall survival rate was 46.7%. The adverse events were mild (gastric, grade 1; and hematologic, grade 1 or 2). No grade 3 or 4 toxicities were associated with the treatment. Evaluation of patients’ quality of life showed no changes during the response period. MCT with cyclophosphamide plus celecoxib is safe and shows a therapeutic effect in advanced breast cancer patients.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Future Medicine
dc.rights
info:eu-repo/semantics/openAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subject
Breast Cancer
dc.subject
Metronomic Chemotherapy
dc.subject
Cyclophosphamide
dc.subject
Celecoxib
dc.subject.classification
Reumatología
dc.subject.classification
Medicina Clínica
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
dc.title
Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2017-07-21T19:06:23Z
dc.journal.volume
9
dc.journal.number
3
dc.journal.pagination
451-462
dc.journal.pais
Reino Unido
dc.journal.ciudad
Londres
dc.description.fil
Fil: Perroud, Herman Andrés. Universidad Nacional de Rosario. Facultad de Ciencias Médicas. Escuela de Ciencias Médicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
dc.description.fil
Fil: Rico, Maria Jose. Universidad Nacional de Rosario. Facultad de Ciencias Médicas. Escuela de Ciencias Médicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
dc.description.fil
Fil: Alasino, Carlos. Instituto de Oncología de Rosario; Argentina
dc.description.fil
Fil: Queralt, Fransisco. Instituto de Oncología de Rosario; Argentina
dc.description.fil
Fil: Mainetti, Leandro Ernesto. Universidad Nacional de Rosario. Facultad de Ciencias Médicas. Escuela de Ciencias Médicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
dc.description.fil
Fil: Pezzotto, Stella Maris. Universidad Nacional de Rosario. Facultad de Ciencias Médicas. Escuela de Ciencias Médicas; Argentina
dc.description.fil
Fil: Rozados, Viviana Rosa. Universidad Nacional de Rosario. Facultad de Ciencias Médicas. Escuela de Ciencias Médicas; Argentina
dc.description.fil
Fil: Scharovsky, Olga Graciela. Universidad Nacional de Rosario. Facultad de Ciencias Médicas. Escuela de Ciencias Médicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
dc.journal.title
Future Oncology
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.2217/fon.12.196
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.futuremedicine.com/doi/10.2217/fon.12.196
Archivos asociados